London, United Kingdom, December 14, 2017 --(PR.com
)-- SMi is delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018.
Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM and subsequently joined the company full time in October 2016.
Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused collaboration programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company’s acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008.
SMi are excited to have interviewed Oliver about his talk and career experience.
Below is a snapshot of his interview:
Q. What do you see as the greatest challenge for those trying to develop RNA Therapeutics?
A. Delivery of the therapeutic molecules to the appropriate target tissues – there are limitations for RNA therapies which we are trying to overcome through a small molecule approach.
Q. What is the most exciting project that you have worked on during your career and why?
A. The project of setting up and launching Storm Therapeutics, establishing a drug discovery organisation in a completely untapped field of biology.
Q. Are there any dangers associated with the use of RNA modifying enzymes?
Check out the full interview, available in the download centre.
Hear more from Oliver Rausch at RNA Therapeutics this February 2018, as he presents "Harnessing the Power of RNA Epigenetics - Targeting RNA Modifying Enzymes for the Treatment of Cancer." www.therapeutics-rna.com/prc
Topics will explore:
- Over 150 different chemical modifications have been identified on RNA molecules.
- The role of these modifications in the maturation and regulation of coding and non-coding RNA is becoming increasingly prominent.
- Utilising the research of world-leading founders Professors Kouzarides and Miska in the field of RNA epigenetics to pioneer the development of small molecule inhibitors of previously untargeted RNA-modifying enzymes (RMEs) to interfere with key RNA pathways and mechanisms.
More About Oliver Rausch:
Oliver has over 15 years’ drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.
Further information is available at: www.therapeutics-rna.com/prc
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics | Advanced Cell Diagnostics | Lypocalyx
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk